Register for our free email digests:
Clinical / R & D
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Medtronic and UnitedHealthcare Encouraged By First-Year Results From Value-Based Agreement
Medtronic and UnitedHealthcare have evidence that their year-old partnership is improving health outcomes in diabetes patients that require intensive insulin delivery. An analysis of more than 6,000 UnitedHealthcare members with diabetes who used Medtronic's MiniMed 630G and previous generation insulin pumps between July 2016 and July 2017 showed 27% fewer preventable hospital admissions compared to plan-participants who were using multiple daily injections of insulin.
Clinical Trials
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Clinical Trials
QUOTED. July 17, 2018. David Brunel.
Biodesix Inc. is acquiring Integrated Diagnostics Inc. for both its flagship XL2 lung-cancer test and to upgrade its ability to develop new pharma companion diagnostics. See what Biodesix CEO David Brunel said about it here.
Open Payments: Zimmer, Medtronic Top List Of Spenders
Major medical device companies paid almost $1bn in consulting fees, royalties, research costs and other expenses to physicians in 2017, the most recent data release from the US Open Payments database shows. Zimmer Biomet reported the highest spending on general physician payments, while Roche and Medtronic topped the list of research spending.
Starts & Stops: July 9-15, 2018
Starts & Stops compiles all the clinical trial announcements, initiations, completions and suspensions tracked by Meddevicetracker. This edition covers trial announcements made between July 9 and July 15, 2018, including announcements from Rex Bionics, Admedus, Osiris Therapeutics, Sanuwave, Abbott, and Biotronik.
New Technology
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Innovation
Global Device Approvals, Weekly Snapshot: July 9-15, 2018
A snapshot of global medical device and diagnostics approvals recorded during the past week in Medtech Insight's Approvals Tracker. This week, Stryker gets a go-ahead to enter the US flow diverter/aneurysm market, and nine CE marks are highlighted.
Global Device Approvals Q2 Shapshot: Coronary Devices Abound
The second quarter of 2018 brought 62 approvals from outside the US, including 46 in Europe, according to Medtech Insight's Approvals Tracker. Among those approvals, 14 were for devices to treat coronary artery disease, and the second most-common indications were obesity and soft-tissue repair. Outside of Europe, Japan had the most non-US approvals in the quarter with five.
US Device Approvals Q2 Snapshot: Cook Clearances Continue; Novel Device Approvals Pick Up
Cook Group maintained strong 510(k) clearance numbers, while US FDA novel-device approvals picked up in Q2 after a slower first quarter. Here's an infographic to spotlight US device approval trends during the second quarter, April through June.
Approvals
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Approvals
Global Device Approvals, Weekly Snapshot: July 9-15, 2018
A snapshot of global medical device and diagnostics approvals recorded during the past week in Medtech Insight's Approvals Tracker. This week, Stryker gets a go-ahead to enter the US flow diverter/aneurysm market, and nine CE marks are highlighted.
Global Device Approvals Q2 Shapshot: Coronary Devices Abound
The second quarter of 2018 brought 62 approvals from outside the US, including 46 in Europe, according to Medtech Insight's Approvals Tracker. Among those approvals, 14 were for devices to treat coronary artery disease, and the second most-common indications were obesity and soft-tissue repair. Outside of Europe, Japan had the most non-US approvals in the quarter with five.
US Device Approvals Q2 Snapshot: Cook Clearances Continue; Novel Device Approvals Pick Up
Cook Group maintained strong 510(k) clearance numbers, while US FDA novel-device approvals picked up in Q2 after a slower first quarter. Here's an infographic to spotlight US device approval trends during the second quarter, April through June.
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.